Articles Posted in Xarelto

Published on:

There is no question that millions of Americans are in need of potentially life-saving medications to prevent strokes from occurring.  In fact, as discussed in a recent Bio Pharma Dive article, strokes are up in the U.S.

Products Liability cases BostonThe conventional treatment for strokes for decades was Warfarin (Coumadin), which is a blood thinning medication.  In 2010, the U.S. Food and Drug Administration (FDA) approved the first of a new class of drugs to compete against Warfarin.  This new class of drugs was labeled new or novel anticoagulants (NAOCs) and works in a different way that Warfarin.  This new drug was called Xarelto, and when it came on the market, many patients started taking it instead of Warfarin. Continue reading

Published on:

Drug companies are big multinational corporations for the most part, and as such report their profits and losses to Wall Street each quarter. That means these firms are very concerned about making money for their shareholders and their executives.  There is no question many medicines they make save a lot of lives. However, when the desire to rake in a profit overshadows the desire to keep people safe and healthy, problems arise.

white pillsOne of the drugs that makes a lot of money for Bayer AG is known as Xarelto.  Xarelto is part of a relatively new class of drugs called new oral anticoagulants (NOACs).  Xarelto is one NOAC manufactured by the German pharmaceutical giant and marketed by its partner in the U.S., Johnson & Johnson, but there other competitors. Those include Savaysa, Elliquis, and Pradaxa.  These drugs are not only competing with each other, but they are also competing with Warfarin (Coumadin).

A recent news article from Yahoo shows that Xarelto was helping drive company sales this past fiscal quarter.

Continue reading

Published on:

According to a recent news article from the Madison St. Clair Record, a plaintiff has just filed a products liability lawsuit against the makers of Xarelto, Bayer Pharmaceuticals and Janssen Research and Development.  Janssen Research and Development was formerly known as Johnson and Johnson Pharmaceuticals Research and is still a wholly owned subsidiary of the pharmaceutical giant.  There were various other subsidiaries of both companies, such as Ortho and Bayer Healthcare AG, that were also named as defendants in this matter, which is common practice in these types of cases.

pillsIn his recent claim, plaintiff says that he took Xarelto because it was a new drug, and his doctor told him he needed a blood thinner or an oral anticoagulant.  Xarelto is a member of a relatively new class of drugs known as new Oral Anticoagulants (NOACs).  This class also included Eliquis, Savaysa, and Pradaxa. Continue reading

Published on:

According to a recent news article from the Cook County Record, a woman has just filed a lawsuit against Bayer and Johnson & Johnson/Janssen Pharmaceuticals, who are the makers and U.S. marketing partners of the New Oral Anticoagulant (NOAC) Xarelto.

whitepillsThis lawsuit alleges that, after taking Xarelto, she suffered serious physical injury.  She is alleging that the drug Xarelto was defectively designed, causing her to suffer these severe medical effects and that the companies failed to warn her of these known defects. Continue reading

Published on:

Last year, the United States Food and Drug Administration (FDA) became aware that a device used to monitor a patient’s blood in Xarelto clinical trials had problems.  Now it has been reported by British Medical Journal, and via FiercePharma, that the two major drug companies (Janssen/Johnson & Johnson and Bayer A.G.) were well aware of this faulty blood monitor during the time it was being used and did not notify any of the study monitors or the FDA.

pills

The device in question is known as the INRatio device, and it was designed to monitor how much Xarelto was being absorbed by patients on a single dose as compared to those who were taking Warfarin (Coumadin).  The reason this is very important has to do with why drug makers claim Xarelto and the other New Oral Anticoagulants (NOACs) are safer and more effective than traditional blood thinning medications like Warfarin. Continue reading

Published on:

According to a recent report from WebMD News, a recent study, which asserted both Xarelto and Pradaxa were superior to Warfarin, found that Xarelto poses a higher risk of serious internal bleeding disorders than its competitor, Pradaxa. The drugs at issue are part of a new class of anticoagulants known as New Oral Anticoagulants (NOACs).  Xarelto, Pradaxa, Eliquis, and Savaysa are the four NOACs approved by the United States Food and Drug Administration (FDA).

untitled-1238929-mThe risk of increased internal bleeding disorders for patients taking Xarelto over patients taking Pradaxa was seen in patients who suffer from a serious medical condition known as atrial fibrillation (Afib).  Afib, is characterized by an irregular heartbeat not caused by a heart valve defect.  If this sounds familiar to you even though you do not suffer from Afib, it might be because Saturday Night Live alumni actor Kevin Nealon appears in a commercial where he discusses his own struggles with Afib and how taking Xarelto has helped him to lead a normal life. Continue reading

Published on:

For many years, if someone needed a blood thinner, he or she would take Warfarin (Coumadin).  This product is relatively safe and there are not many side effects, so long as a person carefully monitors his or her diet and has regular blood tests so their doctor can check the blood chemistry to see how the drug is being absorbed.

prescription-300x201The reason it is important to monitor the absorption level of Warfarin is because if the level is off, it can result in a serious internal bleeding disorders.  While this is a serious concern, as this is no minor side effect, it is easy to avoid so long as you are compliant with your medication. In the event a patient has an internal bleeding disorder and goes to the emergency room, the ER doctors will be able to administer a reversal agent (antidote) that will stop the anti-clotting effect, which, in turn, will allow the body to clot again so the internal bleeding will stop.  It should be noted that reason it is important for a patient to monitor his or her diet is because certain foods high in vitamin K like dark greens will affect the absorption rate of Warfarin, and that can lead to serious problems. Continue reading

Published on:

The makes of Xarelto (Bayer and Johnson & Johnson) took a major hit this week in terms of the future of there flagship drug.  Xarelto is a member of a relatively new class of drugs called New Oral Anticoagulants (NOACs).  NOACs are used for patients who suffer from a series of medical conditions including deep vein thrombosis (DVT) and atrial fibrillation (Afib).  Afib is a serious medical condition that causes an irregular heartbeat when the patient does not have a heart valve defect.

whitepillsIn addition to Xarelto, Pradaxa, Eliquis and Savaysa are members of this new class of NOACs.  Traditionally, before these medications were on the market, patients would take Warfarin (Coumadin) as a blood thinner.  Warfarin is known to work and is relatively safe as long as patients do what they are told to do by their doctors.  However, since patients do not always do what they are told, the drug is not always so convenient to take and may result in a serious internal bleeding disorder.  However, if a patient does suffer from internal bleeding, a doctor can prescribe a reversal agent (antidote) to allow the patient to clot normally so the bleeding will stop. Continue reading

Published on:

There is no question that Xarelto has been linked to a lot of serious bleeding disorders, many of which resulted in death.  There are many reasons the drug has proven so dangerous to users, but a lot of the problems are result of the reportedly negligent manner in which Bayer and Janssen Pharmaceuticals performed the safety testing and informed the U.S. Food and Drug Administration (FDA) of the Results.

Pills pouring from a medication bottle

According to a recent news feature from Forbes, one plaintiff’s lawyer that handles Xarelto injury lawsuits states that these experiments were conducted in the same manner that young students would do in an elementary school science fair when making their projects.  Continue reading

Published on:

A man from Florida has filed a new Xarelto injury lawsuit against Janssen Pharmaceuticals (a division of Johnson & Johnson, which is the U.S. marketing partner of Xarelto) and Bayer A.G. which is the German pharmaceutical giant that manufactures the medication. As part of this lawsuit, he is claiming negligent manufacture of a defective drug, among several other related claims.

perscription-drug-case-1156714-mThe lawsuit was filed in a United States District Court and technically has several more named defendants than listed above because each of these other companies have several wholly owned subsidiaries that were involved in the manufacture and marketing of Xarelto according to a recent news article from the Louisiana Record. Continue reading